MHRA issues reminder to use Yellow Card reporting for suspected ADRs associated with pregnancy

MHRA issues reminder to use Yellow Card reporting for suspected ADRs associated with pregnancy

July 19 2018 The medicines regulator has issued a Drug Safety Update relating to suspected...

APPG calls for long term conditions to be part of new pharmacy contract

APPG calls for long term conditions to be part of new pharmacy contract

July 16 2018 Community pharmacy’s involvement in managing long term conditions should be...

NICE updates guideline on rheumatoid arthritis

NICE updates guideline on rheumatoid arthritis

July 13 2018 NICE has issued a new version of its guideline on the management of rheumatoid...

RPS seeks views on draft guidance around polypharmacy

RPS seeks views on draft guidance around polypharmacy

July 13 2018 The Royal Pharmaceutical Society is seeking comments to hone draft guidance on...

NMS sees 4.5% referral rate to GP for newly prescribed antihypertensives

NMS sees 4.5% referral rate to GP for newly prescribed antihypertensives

July 11 2018 New Medicines Service data indicates community pharmacists manage 19 out of 20...

  • MHRA issues reminder to use Yellow Card reporting for suspected ADRs associated with pregnancy

    MHRA issues reminder to use Yellow Card reporting for suspected ADRs associated with pregnancy

    Thursday, 19 July 2018 10:29
  • APPG calls for long term conditions to be part of new pharmacy contract

    APPG calls for long term conditions to be part of new pharmacy contract

    Monday, 16 July 2018 15:44
  • NICE updates guideline on rheumatoid arthritis

    NICE updates guideline on rheumatoid arthritis

    Friday, 13 July 2018 12:51
  • RPS seeks views on draft guidance around polypharmacy

    RPS seeks views on draft guidance around polypharmacy

    Friday, 13 July 2018 12:47
  • NMS sees 4.5% referral rate to GP for newly prescribed antihypertensives

    NMS sees 4.5% referral rate to GP for newly prescribed antihypertensives

    Wednesday, 11 July 2018 13:02

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

A inspection imageJune 19 2018

A practice-based audit will seek to explore community pharmacy’s contribution in supporting girls and women of childbearing potential who need to take valproate medicines.

Launched by the Company Chemists’ Association, the audit tool has been designed to help pharmacists and their teams review and reflect on their current practice and to assess what changes may need to be made. The first phase of the audit will begin in July, and the second phase will begin in November.

The audit follows on from changes to the medicines licences for valproate medicines introduced earlier this year meaning the products should not be used in pregnancy and women of child bearing potential. Those taking valproate should be made aware of the risks of teratogenicity and be on a planned pregnancy progamme as appropriate.

While the audit is being sent out to CCA member pharmacies, the Association is urging all community pharmacy teams to participate. The audit materials can be downloaded from the CCA site (link below).

Kate Livesey, the CCA’s Policy & Programmes Manager, said: “Community pharmacy teams play a vital role in the care of patients taking these high-risk medicines. Given the importance of this year’s topic, we would like to see pharmacy teams from all across the country getting involved in our audit and reviewing their current practice.  

“We’re really keen to build a body of evidence from across the whole sector that demonstrates what pharmacy teams are doing to improve care and minimise the risk of harm around valproate in pregnancy.”  

PSNC has lent its support to the launch of the audit. Alastair Buxton, Director of NHS Services, at PSNC said: “Patient safety is always a priority in community pharmacy and this audit provides a great opportunity to make a difference to patient safety by focussing on a high-risk medicine associated with birth defects and developmental disorders. 

“Community pharmacy teams are in an ideal position to provide information and advice to women and girls who have been prescribed this medicine, ensuring they get the crucial support they need. This audit is an excellent option for contractors to complete to meet the Community Pharmacy Contractual Framework requirement to undertake a practice-based clinical audit.”

Links:
CCA announcement      
CCA Valproate audit resource   
PSNC comment             

Practice News

July 19 2018 The medicines regulator has issued a Drug Safety Update relating to suspected adverse drug reactions associated with medicines taken during pregnancy.
July 11 2018 New Medicines Service data indicates community pharmacists manage 19 out of 20 hypertensive patients without the need to refer a patient back to the GP. Analysis of 131,419 patient...